Source comparison
BPC-157 + LL-37 Stack: Research Protocol Comparison
Primary Mechanism VEGF upregulation, immune modulation, tissue repair signalling Direct bacterial membrane disruption, endotoxin neutralisation, immune cell recruitment Dual-pathway: immune restoration + direct bactericidal activity Stack addresses both immune
This comparison does not assign a generated winner or score.
- Primary Mechanism
- VEGF upregulation, immune modulation, tissue repair signalling
- Direct bacterial membrane disruption, endotoxin neutralisation, immune cell recruitment
- Dual-pathway: immune restoration + direct bactericidal activity
- Stack addresses both immune dysfunction and pathogen persistence simultaneously
- Dosing Range (Research)
- 250–500 mcg/day subcutaneous
- 2–5 mg/day subcutaneous
- BPC-157 250–500 mcg + LL-37 2–5 mg daily, administered separately
- Doses reflect published pre-clinical and investigational protocols. Not clinical recommendations
- Biofilm Activity
- None demonstrated. Works by restoring immune access to infection site
- Direct biofilm disruption at 5–20 μg/mL tissue concentration
- Synergistic: BPC-157 increases immune/peptide penetration, LL-37 degrades matrix
- Monotherapies leave one pathway unaddressed; stack targets both
- Inflammation Modulation
- Anti-inflammatory via IL-6/TNF-alpha reduction, IL-10 upregulation
- Immunomodulatory but primarily pro-inflammatory during active infection
- Balanced: BPC-157 prevents excessive inflammation while LL-37 maintains pathogen clearance
- Stack may reduce collateral tissue damage from prolonged immune activation
- Published Research Quality
- Primarily rodent models; limited human data
- Human observational studies; some Phase 2 antimicrobial trials
- No published dual-stack clinical trials; hypothesis-driven investigational use
- Evidence is pre-clinical; human efficacy data does not yet exist